Production Of GSK's Ziagen HIV Oral Liquid Medicine

Bottles of Ziagen, an HIV oral liquid medication, move down the packaging line at the GlaxoSmithKline Canada Inc. headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
Bottles of Ziagen, an HIV oral liquid medication, move down the packaging line at the GlaxoSmithKline Canada Inc. headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
Production Of GSK's Ziagen HIV Oral Liquid Medicine
EINE LIZENZ KAUFEN
Wie darf ich dieses Bild verwenden?
475,00 €
EUR

DETAILS

Einschränkungen:
Bei kommerzieller Verwendung sowie für verkaufsfördernde Zwecke kontaktieren Sie bitte Ihr lokales Büro.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Bildnachweis:
Bloomberg / Kontributor
Redaktionell #:
107630282
Kollektion:
Bloomberg
Erstellt am:
13. Dezember 2010
Hochgeladen am:
Lizenztyp:
Releaseangaben:
Kein Release verfügbar. Weitere Informationen
Quelle:
Bloomberg
Objektname:
GLAXO